Goldfinch Bio, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Cambridge MA United States (2016)

Organization Overview

First Clinical Trial
2019
NCT03970122
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Goldfinch Bio, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

gfb-887 (3 trials)

Drugs in Phase 1 Trials (1)

gfb-024 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Complications (Phase 2)

Diabetes Mellitus (Phase 2)

Diabetic Nephropathies (Phase 2)

Endocrine System Diseases (Phase 2)

Glomerulonephritis (Phase 2)

Glomerulosclerosis, Focal Segmental (Phase 2)

Kidney Diseases (Phase 2)

Nephritis (Phase 2)

Nephrosis (Phase 2)

Nephrosis, Lipoid (Phase 2)

Nephrotic Syndrome (Phase 2)

Urologic Diseases (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 2